Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/41216
Título : Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions
Autor: Jamilloux, Yvan
Henry, Thomas
Belot, Alexandre
Viel, Sébastien
Fauter, Maxime
El Jammal, Thomas
Walzer, Thierry
François, Bruno
Sève, Pascal
Palavras-chave: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
COVID-19
Cytokine storm
Tocilizumab
Anakinra
Type-I interferon
Publicador: Elsevier
Data da publicação: Mai-2020
Referência: JAMILLOUX, Y. et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmunity Reviews, [S.l.], May 2020. No prelo.
Abstract: The coronavirus disease-19 pandemic (COVID-19), which appeared in China in December 2019 and rapidly spread throughout the world, has forced clinicians and scientists to take up extraordinary challenges. This unprecedented situation led to the inception of numerous fundamental research protocols and many clinical trials. It quickly became apparent that although COVID-19, in the vast majority of cases, was a benign disease, it could also develop a severe form with sometimes fatal outcomes. Cytokines are central to the pathophysiology of COVID-19; while some of them are beneficial (type-I interferon, interleukin-7), others appear detrimental (interleukin-1β, -6, and TNF-α) particularly in the context of the so-called cytokine storm. Yet another characteristic of the disease has emerged: concomitant immunodeficiency, notably involving impaired type-I interferon response, and lymphopenia. This review provides an overview of current knowledge on COVID-19 immunopathology. We discuss the defective type-I IFN response, the theoretical role of IL-7 to restore lymphocyte repertoire, as well as we mention the two patterns observed in severe COVID-19 (i.e. interleukin-1β-driven macrophage activation syndrome vs. interleukin-6-driven immune dysregulation). Next, reviewing current evidence drawn from clinical trials, we examine a number of cytokine and anti-cytokine therapies, including interleukin-1, -6, and TNF inhibitors, as well as less targeted therapies, such as corticosteroids, chloroquine, or JAK inhibitors.
URI: https://www.sciencedirect.com/science/article/pii/S1568997220301294
http://repositorio.ufla.br/jspui/handle/1/41216
Idioma: en_US
Aparece nas coleções:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.